Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 258

1.

Typical physics Ph.D. admissions criteria limit access to underrepresented groups but fail to predict doctoral completion.

Miller CW, Zwickl BM, Posselt JR, Silvestrini RT, Hodapp T.

Sci Adv. 2019 Jan 23;5(1):eaat7550. doi: 10.1126/sciadv.aat7550. eCollection 2019 Jan.

2.

[Spatial and differential income pattern of households of adolescents and young adults who are victims of maxillofacial injuries resulting from firearm aggression].

Silva CJP, Paiva PCP, Paula LPP, Fonseca JFB, Silvestrini RA, Naves MD, Moura ACM, Ferreira EFE.

Cien Saude Colet. 2018 Apr;23(4):1281-1292. doi: 10.1590/1413-81232018234.14652016. Portuguese.

3.

Are Androgen and Estrogen Receptors in DCIS Patients Prognostic Indicators of Relapse Independently of Treatment?

Ravaioli S, Puccetti M, Tumedei MM, Silvestrini R, Bedei L, Bravaccini S.

Appl Immunohistochem Mol Morphol. 2019 Apr;27(4):301-305. doi: 10.1097/PAI.0000000000000582.

PMID:
28968271
4.

Incidence and prevalence of NMOSD in Australia and New Zealand.

Bukhari W, Prain KM, Waters P, Woodhall M, O'Gorman CM, Clarke L, Silvestrini RA, Bundell CS, Abernethy D, Bhuta S, Blum S, Boggild M, Boundy K, Brew BJ, Brown M, Brownlee WJ, Butzkueven H, Carroll WM, Chen C, Coulthard A, Dale RC, Das C, Dear K, Fabis-Pedrini MJ, Fulcher D, Gillis D, Hawke S, Heard R, Henderson APD, Heshmat S, Hodgkinson S, Jimenez-Sanchez S, Killpatrick T, King J, Kneebone C, Kornberg AJ, Lechner-Scott J, Lin MW, Lynch C, Macdonell R, Mason DF, McCombe PA, Pender MP, Pereira JA, Pollard JD, Reddel SW, Shaw C, Spies J, Stankovich J, Sutton I, Vucic S, Walsh M, Wong RC, Yiu EM, Barnett MH, Kermode AG, Marriott MP, Parratt JDE, Slee M, Taylor BV, Willoughby E, Wilson RJ, Vincent A, Broadley SA.

J Neurol Neurosurg Psychiatry. 2017 Aug;88(8):632-638. doi: 10.1136/jnnp-2016-314839. Epub 2017 May 26.

PMID:
28550069
5.

Comparison of two extractable nuclear antigen testing algorithms: ALBIA versus ELISA/line immunoassay.

Chandratilleke D, Silvestrini R, Culican S, Campbell D, Byth-Wilson K, Swaminathan S, Lin MW.

Pathology. 2016 Aug;48(5):491-7. doi: 10.1016/j.pathol.2016.04.004. Epub 2016 Jun 14.

PMID:
27316331
6.

Validation of a phospholipase A2 receptor antibody ELISA in an Australian cohort with membranous glomerulonephritis.

Ong L, Silvestrini R, Chapman J, Fulcher DA, Lin MW.

Pathology. 2016 Apr;48(3):242-6. doi: 10.1016/j.pathol.2016.02.001. Epub 2016 Mar 8.

PMID:
27020499
7.

Maxillofacial Injuries as Markers of Interpersonal Violence in Belo Horizonte-Brazil: Analysis of the Socio-Spatial Vulnerability of the Location of Victim's Residences.

Silva CJ, Moura AC, Paiva PC, Ferreira RC, Silvestrini RA, Vargas AM, de Paula LP, Naves MD, Ferreira e Ferreira E.

PLoS One. 2015 Aug 14;10(8):e0134577. doi: 10.1371/journal.pone.0134577. eCollection 2015.

8.

Role of androgen and estrogen receptors as prognostic and potential predictive markers of ductal carcinoma in situ of the breast.

Tumedei MM, Silvestrini R, Ravaioli S, Massa I, Maltoni R, Rocca A, Folli S, Buggi F, Curcio A, Serra L, Puccetti M, Amadori D, Bravaccini S.

Int J Biol Markers. 2015 Nov 11;30(4):e425-8. doi: 10.5301/jbm.5000163.

PMID:
26165687
9.

Comparative study of five serological assays for the diagnosis of paraneoplastic pemphigus.

Kelly S, Culican S, Silvestrini RA, Vu J, Schifter M, Fulcher DA, Lin MW.

Pathology. 2015 Jan;47(1):58-61. doi: 10.1097/PAT.0000000000000196.

PMID:
25474518
10.

New biomarkers to predict the evolution of in situ breast cancers.

Bravaccini S, Tumedei MM, Scarpi E, Zoli W, Rengucci C, Serra L, Curcio A, Buggi F, Folli S, Rocca A, Maltoni R, Puccetti M, Amadori D, Silvestrini R.

Biomed Res Int. 2014;2014:159765. doi: 10.1155/2014/159765. Epub 2014 Aug 26.

11.

A dual-fixed neutrophil substrate improves interpretation of antineutrophil cytoplasmic antibodies by indirect immunofluorescence.

Lin MW, Silvestrini RA, Culican S, Campbell D, Fulcher DA.

Am J Clin Pathol. 2014 Sep;142(3):325-30. doi: 10.1309/AJCPG02FGQVAUSIU.

PMID:
25125622
12.

Efficacy of different sequences of radio- and chemotherapy in experimental models of human melanoma.

Arienti C, Zoli W, Pignatta S, Carloni S, Paganelli G, Ulivi P, Romeo A, Menghi E, Sarnelli A, Medri L, Polico R, Silvestrini R, Tesei A.

J Cell Physiol. 2014 Oct;229(10):1548-56. doi: 10.1002/jcp.24598.

PMID:
24591063
13.

Prolonged exposure to (R)-bicalutamide generates a LNCaP subclone with alteration of mitochondrial genome.

Pignatta S, Arienti C, Zoli W, Di Donato M, Castoria G, Gabucci E, Casadio V, Falconi M, De Giorgi U, Silvestrini R, Tesei A.

Mol Cell Endocrinol. 2014 Jan 25;382(1):314-324. doi: 10.1016/j.mce.2013.10.022. Epub 2013 Oct 25.

PMID:
24397920
14.

Benefit from anthracyclines in relation to biological profiles in early breast cancer.

Rocca A, Bravaccini S, Scarpi E, Mangia A, Petroni S, Puccetti M, Medri L, Serra L, Ricci M, Cerasoli S, Biglia N, Maltoni R, Giunchi DC, Gianni L, Tienghi A, Brandi M, Faedi M, Sismondi P, Paradiso A, Silvestrini R, Amadori D.

Breast Cancer Res Treat. 2014 Apr;144(2):307-18. doi: 10.1007/s10549-013-2819-0. Epub 2014 Jan 1. Erratum in: Breast Cancer Res Treat. 2014 Apr;144(2):319. Faedi, Monica [corrected to Faedi, Marina].

PMID:
24381054
15.

DNA Methylation profiles as predictors of recurrence in non muscle invasive bladder cancer: an MS-MLPA approach.

Casadio V, Molinari C, Calistri D, Tebaldi M, Gunelli R, Serra L, Falcini F, Zingaretti C, Silvestrini R, Amadori D, Zoli W.

J Exp Clin Cancer Res. 2013 Nov 19;32:94. doi: 10.1186/1756-9966-32-94.

16.

In vitro irradiation system for radiobiological experiments.

Tesei A, Sarnelli A, Arienti C, Menghi E, Medri L, Gabucci E, Pignatta S, Falconi M, Silvestrini R, Zoli W, D'Errico V, Romeo A, Parisi E, Polico R.

Radiat Oncol. 2013 Nov 1;8:257. doi: 10.1186/1748-717X-8-257.

17.

Role of quantitative and qualitative characteristics of free circulating DNA in the management of patients with non-small cell lung cancer.

Ulivi P, Silvestrini R.

Cell Oncol (Dordr). 2013 Dec;36(6):439-48. doi: 10.1007/s13402-013-0155-3. Epub 2013 Nov 1. Review.

PMID:
24177991
18.

Biofunctional characteristics of in situ and invasive breast carcinoma.

Bravaccini S, Granato AM, Medri L, Foca F, Falcini F, Zoli W, Ricci M, Lanzanova G, Masalu N, Serra L, Buggi F, Folli S, Silvestrini R, Amadori D.

Cell Oncol (Dordr). 2013 Jul;36(4):303-10. doi: 10.1007/s13402-013-0135-7. Epub 2013 Jun 27.

PMID:
23807750
19.

Peripheral blood miR-328 expression as a potential biomarker for the early diagnosis of NSCLC.

Ulivi P, Foschi G, Mengozzi M, Scarpi E, Silvestrini R, Amadori D, Zoli W.

Int J Mol Sci. 2013 May 16;14(5):10332-42. doi: 10.3390/ijms140510332.

20.

Cell proliferation of the primary tumor predicts ipsilateral axillary node disease in elderly breast cancer patients.

Silvestrini R, Martelli G, Miceli R, Agresti R, Veneroni S, Daidone MG.

Int J Biol Markers. 2013 Apr 23;28(1):24-31. doi: 10.5301/JBM.2013.10574.

PMID:
23558937
21.

Urine cell-free DNA integrity as a marker for early prostate cancer diagnosis: a pilot study.

Casadio V, Calistri D, Salvi S, Gunelli R, Carretta E, Amadori D, Silvestrini R, Zoli W.

Biomed Res Int. 2013;2013:270457. doi: 10.1155/2013/270457. Epub 2013 Feb 13.

22.

Multiple marker detection in peripheral blood for NSCLC diagnosis.

Ulivi P, Mercatali L, Casoni GL, Scarpi E, Bucchi L, Silvestrini R, Sanna S, Monteverde M, Amadori D, Poletti V, Zoli W.

PLoS One. 2013;8(2):e57401. doi: 10.1371/journal.pone.0057401. Epub 2013 Feb 26.

23.

Role of conventional chemosensitivity test and tissue biomarker expression in predicting response to treatment of peritoneal carcinomatosis from colon cancer.

Arienti C, Tesei A, Verdecchia GM, Framarini M, Virzì S, Grassi A, Scarpi E, Turci L, Silvestrini R, Amadori D, Zoli W.

Clin Colorectal Cancer. 2013 Jun;12(2):122-7. doi: 10.1016/j.clcc.2012.11.006. Epub 2013 Jan 16.

PMID:
23332421
24.

SLUG silencing increases radiosensitivity of melanoma cells in vitro.

Arienti C, Tesei A, Carloni S, Ulivi P, Romeo A, Ghigi G, Menghi E, Sarnelli A, Parisi E, Silvestrini R, Zoli W.

Cell Oncol (Dordr). 2013 Apr;36(2):131-9. doi: 10.1007/s13402-012-0120-6. Epub 2012 Dec 19.

PMID:
23250725
25.

Urine cell-free DNA integrity as a marker for early bladder cancer diagnosis: preliminary data.

Casadio V, Calistri D, Tebaldi M, Bravaccini S, Gunelli R, Martorana G, Bertaccini A, Serra L, Scarpi E, Amadori D, Silvestrini R, Zoli W.

Urol Oncol. 2013 Nov;31(8):1744-50. doi: 10.1016/j.urolonc.2012.07.013. Epub 2012 Nov 7.

PMID:
23141783
26.

EGFR and K-ras mutations in cytologic samples from fine-needle aspirates in NSCLC patients.

Ulivi P, Zoli W, Chiadini E, Capelli L, Candoli P, Calistri D, Silvestrini R, Puccetti M.

Eur Respir J. 2012 Jul;40(1):267-9. doi: 10.1183/09031936.00204511. No abstract available.

27.

Predictive role of telomerase activity in the clinical outcome of patients with benign lesions of the uterine cervix or CIN.

Bravaccini S, Amadori A, Scarpi E, Tumedei MM, Zoli W, Silvestrini R.

Anal Cell Pathol (Amst). 2012;35(5-6):377-80. doi: 10.3233/ACP-2012-0066.

28.

Organosulfur derivatives of the HDAC inhibitor valproic acid sensitize human lung cancer cell lines to apoptosis and to cisplatin cytotoxicity.

Tesei A, Brigliadori G, Carloni S, Fabbri F, Ulivi P, Arienti C, Sparatore A, Del Soldato P, Pasini A, Amadori D, Silvestrini R, Zoli W.

J Cell Physiol. 2012 Oct;227(10):3389-96. doi: 10.1002/jcp.24039.

PMID:
22212895
29.

Detection of HER2 and Topo 2 in breast cancers: comparison between MLPA and FISH approaches.

Bravaccini S, Rengucci C, Medri L, Zoli W, Silvestrini R, Amadori D.

J Clin Pathol. 2012 Feb;65(2):183-5. doi: 10.1136/jclinpath-2011-200342. Epub 2011 Oct 29.

PMID:
22039286
30.

Simulating fire regimes in the Amazon in response to climate change and deforestation.

Silvestrini RA, Soares-Filho BS, Nepstad D, Coe M, Rodrigues H, Assunção R.

Ecol Appl. 2011 Jul;21(5):1573-90.

PMID:
21830703
31.

Peritoneal carcinomatosis from ovarian cancer: chemosensitivity test and tissue markers as predictors of response to chemotherapy.

Arienti C, Tesei A, Verdecchia GM, Framarini M, Virzì S, Grassi A, Scarpi E, Turci L, Silvestrini R, Amadori D, Zoli W.

J Transl Med. 2011 Jun 20;9:94. doi: 10.1186/1479-5876-9-94.

32.

Combining cytology, TRAP assay, and FISH analysis for the detection of bladder cancer in symptomatic patients.

Bravaccini S, Casadio V, Gunelli R, Bucchi L, Zoli W, Amadori D, Silvestrini R, Calistri D.

Ann Oncol. 2011 Oct;22(10):2294-8. doi: 10.1093/annonc/mdq740. Epub 2011 Feb 21.

PMID:
21339385
33.

Research trends for early cancer biomarker detection in Italy: an integrated program in oncology (PIO) survey.

Verderio P, Mangia A, Orlando C, Belfiglio M, Marchetti A, Bertario L, Chiappetta G, Gion M, Tonini GP, Podo F, Vocaturo A, Silvestrini R, Lombardo C, Paradiso A.

Tumori. 2010 Sep-Oct;96(5):721-5.

PMID:
21302619
34.

Activity of different anthracycline formulations in hormone-refractory prostate cancer cell lines: role of Golgi apparatus.

Fabbri F, Zoli W, Carloni S, Ulivi P, Arienti C, Brigliadori G, Montanari M, Tesei A, Silvestrini R, Amadori D.

J Cell Physiol. 2011 Nov;226(11):3035-42. doi: 10.1002/jcp.22654.

PMID:
21302303
35.

Increased levels of free circulating DNA in patients with idiopathic pulmonary fibrosis.

Casoni GL, Ulivi P, Mercatali L, Chilosi M, Tomassetti S, Romagnoli M, Ravaglia C, Gurioli C, Gurioli C, Zoli W, Silvestrini R, Poletti V.

Int J Biol Markers. 2010 Oct-Dec;25(4):229-35.

PMID:
21161945
36.

Randomized phase III trial of adjuvant epirubicin followed by cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) versus CMF followed by epirubicin in patients with node-negative or 1-3 node-positive rapidly proliferating breast cancer.

Amadori D, Silvestrini R, De Lena M, Boccardo F, Rocca A, Scarpi E, Schittulli F, Brandi M, Maltoni R, Serra P, Ponzone R, Biglia N, Gianni L, Tienghi A, Valerio MR, Bonginelli P, Amaducci L, Faedi M, Baldini E, Paradiso A.

Breast Cancer Res Treat. 2011 Feb;125(3):775-84. doi: 10.1007/s10549-010-1257-5. Epub 2010 Dec 4.

37.

Fecal DNA for noninvasive diagnosis of colorectal cancer in immunochemical fecal occult blood test-positive individuals.

Calistri D, Rengucci C, Casadei Gardini A, Frassineti GL, Scarpi E, Zoli W, Falcini F, Silvestrini R, Amadori D.

Cancer Epidemiol Biomarkers Prev. 2010 Oct;19(10):2647-54. doi: 10.1158/1055-9965.EPI-10-0291.

38.

False-positive intercellular cement substance antibodies due to group A/B red cell antibodies: frequency and approach.

Lee FJ, Silvestrini R, Fulcher DA.

Pathology. 2010;42(6):574-7. doi: 10.3109/00313025.2010.508792.

PMID:
20854077
39.

Innovative Breast Cancer Biomarkers.

Paradiso A, Silvestrini R, Chiappetta G.

Breast Care (Basel). 2010;5(2):60-61. Epub 2010 Apr 13. No abstract available.

40.

Role of Brazilian Amazon protected areas in climate change mitigation.

Soares-Filho B, Moutinho P, Nepstad D, Anderson A, Rodrigues H, Garcia R, Dietzsch L, Merry F, Bowman M, Hissa L, Silvestrini R, Maretti C.

Proc Natl Acad Sci U S A. 2010 Jun 15;107(24):10821-6. doi: 10.1073/pnas.0913048107. Epub 2010 May 26.

41.

In vitro and in vivo antitumor efficacy of docetaxel and sorafenib combination in human pancreatic cancer cells.

Ulivi P, Arienti C, Zoli W, Scarsella M, Carloni S, Fabbri F, Tesei A, Chiadini E, Orlandi A, Passeri D, Zupi G, Milandri C, Silvestrini R, Amadori D, Leonetti C.

Curr Cancer Drug Targets. 2010 Sep;10(6):600-10. Review.

PMID:
20491617
42.

Tyrosine kinase inhibitors gefitinib, lapatinib and sorafenib induce rapid functional alterations in breast cancer cells.

Carloni S, Fabbri F, Brigliadori G, Ulivi P, Silvestrini R, Amadori D, Zoli W.

Curr Cancer Drug Targets. 2010 Jun;10(4):422-31.

PMID:
20384581
43.

Accuracy of urine telomerase activity to detect bladder cancer in symptomatic patients.

Casadio V, Bravaccini S, Gunelli R, Nanni O, Zoli W, Amadori D, Calistri D, Silvestrini R.

Int J Biol Markers. 2009 Oct-Dec;24(4):253-7.

PMID:
20082275
44.

Low-dose taxotere enhances the ability of sorafenib to induce apoptosis in gastric cancer models.

Tesei A, Leonetti C, Zupi G, Scarsella M, Brigliadori G, Ulivi P, Fabbri F, Arienti C, Amadori D, Passardi A, Silvestrini R, Zoli W.

J Cell Mol Med. 2011 Feb;15(2):316-26. doi: 10.1111/j.1582-4934.2009.00993.x.

45.

Chromosome 1p and 19q evaluation in low-grade oligodendrogliomas: a descriptive study.

Molinari C, Iorio P, Medri L, Ballardini M, Guiducci G, Cremonini AM, Cerasoli S, Riccioni L, Faedi M, Mariani GA, Zoli W, Silvestrini R, Calistri D.

Int J Mol Med. 2010 Jan;25(1):145-51.

PMID:
19956913
46.

Docetaxel-ST1481 sequence exerts a potent cytotoxic activity on hormone-resistant prostate cancer cells by reducing drug resistance-related gene expression.

Fabbri F, Brigliadori G, Carloni S, Ulivi P, Tesei A, Silvestrini R, Amadori D, Zoli W.

Prostate. 2010 Feb 1;70(2):219-27. doi: 10.1002/pros.21055.

PMID:
19790230
47.

The Integrated Oncology Program of the Italian Ministry of Health. Analytical and clinical validation of new biomarkers for early diagnosis: network, resources, methodology, quality control, and data analysis.

Paradiso A, Mangia A, Orlando C, Verderio P, Belfiglio M, Marchetti A, Bertario L, Chiappetta G, Gion M, Tonini GP, Podo F, Vocaturo A, Silvestrini R, Romani M, Belloni E, Cavallo D, Ulivi P, Tommasi S, Steffan A, Russo A, Alessio M, Calistri D, Zancan M, Parrela P, Broggini M, Giuseppe A, Buttitta F, Finocchiaro G, Mazzocco K, Veronesi G, Landuzzi L, Benevolo M, Mariani L, De Marco F, Venuti A, Giannelli G, Quaranta M, Trojano V.

Int J Biol Markers. 2009 Jul-Sep;24(3):119-29.

PMID:
19787622
48.

The current role of telomerase in the diagnosis of bladder cancer.

Bravaccini S, Casadio V, Amadori D, Calistri D, Silvestrini R.

Indian J Urol. 2009 Jan;25(1):40-6. doi: 10.4103/0970-1591.45535.

49.

Role of RAF/MEK/ERK pathway, p-STAT-3 and Mcl-1 in sorafenib activity in human pancreatic cancer cell lines.

Ulivi P, Arienti C, Amadori D, Fabbri F, Carloni S, Tesei A, Vannini I, Silvestrini R, Zoli W.

J Cell Physiol. 2009 Jul;220(1):214-21. doi: 10.1002/jcp.21753.

PMID:
19288493
50.

Quantitative fluorescence determination of long-fragment DNA in stool as a marker for the early detection of colorectal cancer.

Calistri D, Rengucci C, Molinari C, Ricci E, Cavargini E, Scarpi E, Milandri GL, Fabbri C, Ravaioli A, Russo A, Amadori D, Silvestrini R.

Cell Oncol. 2009;31(1):11-7.

Supplemental Content

Loading ...
Support Center